Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.
Discover how we are working to reimagine PsA and axSpA management
We appreciate the challenges you face in today’s clinic environment – that’s why we’ve created this online events resource where you can connect with the latest evidence and opinions in the management of PsA and axSpA in your own time.
Evolving rheumatology services to support PsA patients in a new world
Join us at the virtual BSR 2021 conference to discuss the PsA patient journey and the impact of COVID-19 on rheumatology practices with our multidisciplinary panel of experts, Antoni Chan, Kirsten MacKay, Julie Begum, and Anusha Patel.
New for 2021
Treating plaque psoriasis (PsO) and psoriatic arthritis (PsA) patients with multiple manifestations
Hear Dr Christos Kasparis and Professor Laura Coates discuss the management of PsO and PsA with multiple manifestations and offer perspectives on the importance of timely screening and treating appropriate patients early with the right biologic.
Paradigm shift: IL-17A inhibition in PsA and axSpA (AS and nr-axSpA)
Hear UK-based rheumatology experts, Laura Coates, Paul Emery, Bruce Kirkham and Raj Sengupta, critically assess the latest clinical trial evidence for IL-17A inhibition with Cosentyx, in the management of PsA and axSpA, and how this can direct future therapy choice.
Best of 2020
Reimagining PsA: Raising the standard of care for patients
As shown at EULAR and BSR, hear insights on treatment strategies for PsA from renowned, international medical experts, Laura Coates, Philip Conaghan, Désirée van der Heijde, Peter Nash and Grace Wright, and discover the latest head-to-head trial data.
AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; BSR, British Society for Rheumatology; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; IL, interleukin; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, plaque psoriasis.